Editorials |
From the Department of Pathology (S.F., D.E.D.), Department of Medicine, Division of Cardiovascular Medicine (S.F., M.F.L.), and Department of Pharmacology (M.F.L.), Vanderbilt University Medical Center, Nashville, Tenn.
Correspondence to Sergio Fazio, Vanderbilt University Medical Center, Division of Cardiovascular Medicine, 383 Preston Research Building, Nashville, TN 37232-6300. E-mail sergio.fazio@vanderbilt.edu
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Ahallmark of the atherosclerotic plaque is the accumulation of lipid-laden foam cells that are derived from macrophages or smooth muscle cells (SMCs).1,2 Cholesterol from modified lipoproteins is taken up and either stored in intracellular lipid droplets or delivered to extracellular cholesterol acceptors. Cellular free cholesterol can be exported to nascent HDL and activate the reverse cholesterol transport system, but when it accumulates in large amounts it can induce toxic changes leading to cell death. Conversely, esterified cholesterol is a more inert form of cholesterol for storage, but is not available for efflux to extracellular cholesterol acceptors. Acyl-coenzyme A (CoA): cholesterol acyltransferase (ACAT) esterifies excess free cholesterol and regulates cellular cholesterol homeostasis. ACAT occurs in two isoforms, ACAT-1 and ACAT-2. Whereas liver and intestine express both ACAT-1 and ACAT-2, macrophages and SMCs express ACAT-1 only.3 Nonselective inhibition of ACAT has the potential to both lower plasma lipids and to reduce foam cell formation.3,4 However, the therapeutic potential of ACAT inhibitors is not without controversy, because data have been published suggesting beneficial effects on experimental atherosclerosis as well as negative effects on macrophage viability.57 Furthermore, elimination of macrophage ACAT-1 is associated with increased atherosclerotic lesion formation in murine models.8 In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Rong et al point to SMCs as a possible explanation for the apparently contradictory effects of ACAT inhibition.9
See page 122
In this study, Rong et al confirm the role of ACAT-1 in the formation of SMC foam cells and show that SMCs
Related Article:
Arterioscler Thromb Vasc Biol 2005 25: 122-127.
This article has been cited by other articles:
![]() |
C. Murphy, G. S. Kanaganayagam, B. Jiang, P. J. Chowienczyk, R. Zbinden, M. Saha, S. Rahman, A. M. Shah, M. S. Marber, and M. T. Kearney Vascular Dysfunction and Reduced Circulating Endothelial Progenitor Cells in Young Healthy UK South Asian Men Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 936 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Rudel, R. G. Lee, and P. Parini ACAT2 Is a Target for Treatment of Coronary Heart Disease Associated With Hypercholesterolemia Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1112 - 1118. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |